Table 4 Characteristics associated with SARS-CoV-2 infection and the COVID-19 pandemic
n = 238 | |
|---|---|
SARS-CoV-2 infection history, yes (%) | 43 (18.1) |
Diagnosis by RT-PCR | 9 (20.9) |
Diagnosis by antigen | 2 (4.7) |
Diagnosis by antibodies | 6 (13.9) |
Diagnosis by clinical | 26 (60.5) |
COVID-19 severity, n (%) | n = 43 |
Asymptomatic | 2 (4.7) |
Mild | 36 (83.7) |
Moderate | 2 (4.7) |
Severe | 3 (6.9) |
COVID-19 vaccination, yes (%) | 132 (55.5) |
BBIBP-CorV/Sinopharm | 102 (77.3) |
Gam-COVID-Vac/Sputnik-V | 26 (19.7) |
CIGB-66/Abdala (vaccine candidate) | 2 (1.5) |
ChAdOx1-S/nCoV-19/AstraZeneca | 1 (0.75) |
BNT162b2/Pfizer-BioNTech | 1 (0.75) |
Problems during the COVID-19 pandemic | n = 210 |
With HIV consultations, yes (%) | 25 (11.9) |
With ART supply, yes (%) | 7 (3.33) |
Consultations in the last 12 months, n (%) | n = 210 |
None | 33 (15.7) |
One visit | 98 (46.7) |
Two visits | 69 (32.9) |
Three or more visits | 10 (4.7) |